Last reviewed · How we verify

NCT06281041: NHIS

Nationwide Cohort Study of Antiplatelet Agents as Primary Prevention

Completed Last updated 14 March 2025
What this trial tests

trial testing Antiplatelet Agents in Coronary Artery Disease in 4,657 participants. Completed in 31 December 2024.

Timeline
1 January 2013
Primary endpoint
31 December 2024
31 December 2024

Quick facts

Lead sponsorSamsung Medical Center
StatusCompleted
Study typeOBSERVATIONAL
Enrollment4,657
Start date1 January 2013
Primary completion31 December 2024
Estimated completion31 December 2024
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Samsung Medical Center

Who can join

Eligibility, any sex, with Coronary Artery Disease or Coronary Artery Stenosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

There is no specific recommendation regarding pharmacologic treatment as primary prevention for patients with intermediate coronary artery stenosis whose revascularization was deferred based on negative fractional flow reserve (FFR). Current nationwide cohort study conducted using Korean National Health Insurance Service database evaluated the safety and efficacy of antiplatelet therapy in patients with intermediate coronary artery stenosis with deferred revascularization based on negative FFR (FFR\>0.80).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Antiplatelet Agents

Trials testing the same drug.

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

Other Samsung Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06281041.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing